FDA Accepts Protocol Amendment for Pivotal Phase 3 Head & Neck Cancer Study, Accelerating Potential Readout

summarizeSummary

Nanobiotix announced FDA acceptance of a protocol amendment for its pivotal Phase 3 head and neck cancer study, which is expected to accelerate the trial readout and potential registration pathway.

check_boxKey Events

• Phase 3 Protocol Amendment Accepted

  The FDA accepted a protocol amendment for the pivotal NANORAY-312 study of JNJ-1900 (NBTXR3) in locally advanced head and neck squamous cell cancers.

• Accelerated Trial Timeline

  The amendment eliminates the previously planned interim analysis and modifies the final analysis to include fewer events, aiming for an earlier readout in the same timeframe as the original interim analysis.

• Potential for Earlier Revenue

  Nanobiotix anticipates this decision could accelerate and expand the global registration pathway, providing an opportunity for earlier increased revenue generation and unlocking hundreds of millions in potential milestone payments from its partner, Johnson & Johnson.

auto_awesomeAnalysis

This filing announces a significant development for Nanobiotix's lead product candidate, JNJ-1900 (NBTXR3). The FDA's acceptance of a protocol amendment for the pivotal NANORAY-312 Phase 3 study in head and neck cancer is a positive signal. By eliminating the interim analysis and modifying the final analysis to require fewer events and occur sooner, the company aims to accelerate the global registration pathway. This could lead to earlier market access and revenue generation, including unlocking hundreds of millions in potential milestone payments from Johnson & Johnson, which is material for the company.